公开(公告)号：US20130011392A1

公开(公告)日：2013-01-10

申请号：US13510705

申请日：2010-11-19

申请人： Joseph Ciccolini ,  Cédric Mercier ,  Jean-François Seitz ,  Laetitia Dahan ,  Athanassios Iliadis ,  L'Houcine Ouafik

发明人： Joseph Ciccolini ,  Cédric Mercier ,  Jean-François Seitz ,  Laetitia Dahan ,  Athanassios Iliadis ,  L'Houcine Ouafik

IPC分类号： C12Q1/34 ,  A61P35/00 ,  A61K33/24 ,  A61K31/7068 ,  A61K39/395

CPC分类号： G01N33/574 ,  C12Q1/34 ,  G01N2333/978 ,  G01N2800/52

摘要： The invention relates to an in vitro method for determining the ability of a patient with cancer to respond to a monochemotherapy or to a polychemotherapy involving the administration of at least one chemotherapeutic agent the liver elimination of which involves cytidine deaminase (CDA), or to be treated by at least one such chemotherapeutic agent, which method comprises determining the CDA activity in a biological sample of the patient, wherein a CDA activity above 6 U/mg of serum sample total protein is indicative of the inability of the patient to respond to the chemotherapy, a CDA activity between 1.1 U/mg and 6 U/mg of serum sample total protein is indicative of the ability of the patient to be treated by the chemotherapeutic agent when said agent is administered in the context of a monochemotherapy, and a CDA activity between 1.4 U/mg and 6 U/mg of serum sample total protein is indicative of the ability of the patient to be treated by the chemotherapeutic agent when said agent is administered in the context of a polychemotherapy.

摘要翻译： 本发明涉及一种用于确定癌症患者对单次疗法或多化疗的能力的体外方法，所述多化疗包括施用至少一种涉及胞苷脱氨酶（CDA）的肝脏消除的化学治疗剂，或者为 由至少一种这样的化学治疗剂治疗，该方法包括确定患者生物样品中的CDA活性，其中高于6U / mg的血清样品总蛋白的CDA活性指示患者不能对 化学疗法，1.1U / mg和6U / mg血清样品总蛋白之间的CDA活性指示当所述药物在单次疗法的上下文中时，由化学治疗剂治疗的患者的能力，以及CDA 1.4U / mg和6U / mg的血清样品总蛋白之间的活性指示当所述药剂是所述药物时，由化学治疗剂治疗的患者的能力 在多化学治疗的背景下进行治疗。

公开(公告)号：US20100166848A1

公开(公告)日：2010-07-01

申请号：US12676013

申请日：2008-09-11

申请人： Joseph Ciccolini ,  Raphaelle Fanciullino

发明人： Joseph Ciccolini ,  Raphaelle Fanciullino

IPC分类号： A61K9/127 ,  A61K31/513 ,  A61P35/00

CPC分类号： A61K9/127 ,  A61K9/00 ,  A61K9/1277 ,  A61K9/1278 ,  A61K31/513 ,  A61K31/7076 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides a pharmaceutical composition comprising liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino). In a preferred embodiment, the liposomes comprise phosphatidylcholine (PC), phosphatidyl-glycol (PG) and sterol, preferably in a molar ratio PC/PG/sterol of 20-80/10-60/15-60. The invention further provides a method for preparing liposomes which coencapsulate 5-fluorouracil (5-FU) and 2′-deoxyinosine (d-Ino), and the use thereof for the manufacture of a medicament for treating cancer in a patient.

摘要翻译： 本发明提供一种药物组合物，其包含将5-氟尿嘧啶（5-FU）和2'-脱氧肌苷（d-Ino）包囊的脂质体。 在优选的实施方案中，脂质体包含磷脂酰胆碱（PC），磷脂酰二醇（PG）和固醇，优选PC / PG /甾醇的摩尔比为20-80 / 10-60 / 15-60。 本发明进一步提供了一种制备包封5-氟尿嘧啶（5-FU）和2'-脱氧肌苷（d-Ino）的脂质体的方法及其在制备用于治疗患者癌症的药物中的用途。